Reports The Distributed Partnering Model for Drug Discovery and Development The major contributors to therapeutic innovations in the 20th century have been the pharmaceutical companies, with biotechnology companies adding significantly over the last twenty-five years. However, these models increasingly have failed in translating the advances of biomedical sciences into innovative products. January 15, 2010 Share: Facebook LinkedIn Twitter Download the Report The Distributed Partnering Model for Drug Discovery and Development pdf We suggest a modern-day paradigm for efficiently advancing new therapeutic products. This “distributed partnering” approach would involve four distinct, independent organizations to collaborate in a risk-adjusted manner to discover, define, develop, and deliver innovative products. The new model would feature the formation of companies called product definition companies (PDC), which would focus solely on advancing innovation through the initial definition research phase. PDCs would consist of a team of experienced professionals who would raise funds to manage several projects simultaneously. PDCs would acquire early-stage discoveries from research institutions and invest in defining product applications with a goal of selling the successful ones to pharmaceutical companies for further development and delivery. Next Reports Characteristics of New Firms: A Comparison by Gender August 29, 2009 Reports Sources of Financing for New Technology Firms: A Comparison by Gender August 10, 2009 Reports The Use of Credit Card Debt by New Firms August 10, 2009